about
Strategies for combining immunotherapy with radiation for anticancer therapyNK cell therapy: targeting disease relapse after hematopoietic stem cell transplantationMembrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cellsA Novel Method for Assessment of Natural Killer Cell Cytotoxicity Using Image CytometryChimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trialsHaploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular TherapyTumor lysing genetically engineered T cells loaded with multi-modal imaging agentspiggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells.Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection.The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cellsIL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors.The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptorCombining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation.Identifying candidate allogeneic NK-cell donors for hematopoietic stem-cell transplantation based on functional phenotype.Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis.Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis.Is there an expiration date for a cord blood unit in storage?Activating and propagating polyclonal gamma delta T cells with broad specificity for malignanciesAntibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells.Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children.In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid LeukemiaC/EBPbeta suppression by interruption of CUGBP1 resulting from a complex rearrangement of MLL.Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7.Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.Repression of GSK3 restores NK cell cytotoxicity in AML patients.Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNγ secretion.Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.Toward eliminating HLA class I expression to generate universal cells from allogeneic donorsMentoring in pediatric oncology: a report from the Children's Oncology Group Young Investigator CommitteeImaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography.Natural killer cells for osteosarcoma.Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients.Natural killer cell adoptive immunotherapy: Coming of age.
P50
Q26796675-3CDBE280-1CD0-494E-964C-7E9777AB2DA4Q26863559-FA118882-11BD-421A-8913-079FE318E681Q27309991-A6BB4148-AE33-4D1F-A8AF-78C87F77EAAEQ27312227-0E2F5F18-EE00-4A03-857F-88E41064188BQ27312288-210AB2B6-4F32-43DB-8EB7-6B0A8BBD1C7EQ28085397-B75E0BA9-C75F-427F-A18B-089825A05DE3Q30441151-D5CEBE40-5DB4-4F8C-9B74-9A38631F339AQ30496580-0D31E465-D3AE-4B38-B5CA-70988A021DF4Q30584839-DA05219D-F5C8-4F70-A7CD-7D40CEA8000EQ30585324-B855C1A2-C937-48F6-B876-2A2E8F0FC66DQ33584049-80D49BE8-2F84-4F6A-A5BE-D6F4F26769B6Q33670036-83D99A13-FA0B-4221-95B3-F734ABF41274Q33852140-150E5E4C-2999-4ECA-B167-C7A49FFC293EQ33862876-E198F705-E6A2-49B1-B894-429F73C33D20Q33917198-16141471-985B-40AF-A0F8-3006333A73FFQ34057048-C76FD6DB-F74F-4862-9E46-227589E396C0Q34069803-A6DD78F1-66DF-4FE0-8BE6-8937965A9CBBQ34088081-3D18CA10-7076-4222-A69C-3CE6EA512328Q34132358-BDA4B6E4-3454-4DF2-AD25-DDC0E0B61051Q34449885-44A23E8C-8E07-425D-95C6-F240B3CD3D33Q34517192-3BE71F0F-D31B-4CFF-8B2A-0A2EB7E94FF9Q34551199-7FC7E2D4-53BF-48E4-BA2B-18733197FA8BQ34987908-246E974B-5B8F-4B3E-8E5E-5AF18F498158Q35034803-5D6748E3-ECD8-457B-B450-14402955E841Q35129248-42A5BCB8-80B0-43EC-A94F-003CA1812429Q35151981-42448E0A-3692-492B-9350-5546B2569F15Q35681332-B2B5214B-63BD-4698-A8F8-B8661DB9EBABQ35850329-5D9740DC-ED0C-4D4E-B9BD-FC876B916DA0Q35988657-A85D3528-9842-4748-B3AB-5B79A93E3106Q36163212-BBC53C8A-FD8F-42EE-AFCF-E81E12479DA6Q36218880-DA161CE1-04ED-4DA0-B75E-90F0EBB1492CQ36768725-1976C151-7685-4C05-9E1A-1C5598E59A2DQ36821168-E3D78D6A-F1A0-4232-961F-2FF97977407FQ36999109-54805FED-E467-4DD1-B4D0-0C5669BA4DD8Q37113074-6EAD549A-47A0-453C-85F7-D1D933D645F4Q37340417-AAD215E6-7209-4B86-AC34-39233879C6CEQ37395931-805689ED-6423-411F-9C68-B86E7135AC87Q38219846-81001ADC-F456-44EB-AB78-FB32356642DAQ38586429-0187BF08-C4D1-47AB-8B03-1FDA852E295AQ38736347-076BA728-3015-4C6A-8BE8-C51B2FAE05E7
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Dean A Lee
@es
Dean A Lee
@nl
Dean A Lee
@sl
Dean A. Lee
@en
type
label
Dean A Lee
@es
Dean A Lee
@nl
Dean A Lee
@sl
Dean A. Lee
@en
prefLabel
Dean A Lee
@es
Dean A Lee
@nl
Dean A Lee
@sl
Dean A. Lee
@en
P106
P1153
35229627500
P21
P2798
P31
P496
0000-0001-6693-5392
P569
2000-01-01T00:00:00Z